Expects PDUFA date around May...ADCOM likely in Q1....EU filing by year end 2013....350mil peak sales by 2022...Attractive tax rate from IP transfer to Dutch subsidiary...Low market valuation versus peers...$14 price objective but could move to high teens on approval. Modest enterprise value. Hospitals are looking for a low cost means to treat infections on a longer term basis MRSA antibiotic....R&D could expand current opportunities for D. D for children...osteomyelitis....bronchoalveolar.lavage study for pneumonia...additional indications beyond skin infections etc. Low market value of 200 mil...
Got a winner here gang IMHO...Patience then patients!
I agree, but I don't think there are any major catalysts till then, so I sold off with small profit and swapped into STML. I think there is huge opportunity in here for next year. I honestly think this stock could be Regeneron in the next couple years. If DRTX gets hit during a market correction, I think I would buy back in.
Nice move. I didnt think DRTX would see 10 again. I like STML but I think its vulnerable to a big dump do to it being only a early small trial. To much time in between news. I started a small position there but wouldnt be shocked to see it hit 15 if there is a market correction.